Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEHYDRATED ALCOHOL vs DIFFERIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dehydrated alcohol (ethanol) causes tissue necrosis by protein denaturation and cellular dehydration, leading to vascular thrombosis and ischemic infarction. It ablates nerve tissue by extracting lipids and precipitating proteins.
Adapalene is a retinoid-like compound that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene expression and normalizing differentiation and proliferation of follicular epithelial cells, reducing comedogenesis and inflammation.
FDA-approved for adjunctive therapy in the treatment of cystic thyroid nodules,Off-label: Neurolysis for celiac plexus block in pancreatic cancer pain,Off-label: Ablation of hepatocellular carcinoma,Off-label: Sclerotherapy for esophageal varices
FDA-approved for the topical treatment of acne vulgaris in patients aged 12 and older. Off-label uses include treatment of photodamage, keratosis pilaris, and actinic keratoses.
Intravenous administration: 0.1-1 m L of sterile dehydrated alcohol (100% ethanol) injected directly into cystic lesions or tumors under imaging guidance. Maximum volume per injection: 1 m L, repeated up to 3 times per session depending on lesion size.
Apply a thin layer of 0.1% gel or cream to affected areas once daily in the evening.
2-4 hours in most individuals at zero-order kinetics; terminal half-life is concentration-dependent due to saturation of alcohol dehydrogenase. Clinically, elimination rate is constant at 15-20 mg/d L/hour in non-tolerant individuals.
Terminal elimination half-life is approximately 14–22 hours; steady-state is achieved within 3–5 days.
Primarily hepatic via alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH); minor metabolism via CYP2E1 at high concentrations.
Adapalene is minimally metabolized in the skin; systemic absorption is low. Any absorbed drug is primarily metabolized in the liver via cytochrome P450 enzymes, likely CYP2C9 and CYP3A4, and excreted in bile as metabolites.
Ethanol is primarily eliminated by hepatic metabolism (90-98%) via alcohol dehydrogenase and aldehyde dehydrogenase, with 2-10% excreted unchanged in urine, breath, and sweat. Renal elimination is minor and variable.
Primarily biliary/fecal (>95%) as unchanged drug and metabolites; renal excretion is negligible.
Negligible (<5%); no specific binding proteins.
Highly protein-bound (>99%), mainly to plasma albumin and lipoproteins.
0.5-0.7 L/kg, approximating total body water. Higher in females due to lower lean body mass.
Large volume of distribution (~14–16 L/kg), indicating extensive tissue binding and distribution.
Oral: ~80-100% due to rapid absorption from stomach and small intestine; IV: 100%.
Topical absorption is minimal (<5% of applied dose); systemic bioavailability is negligible.
No dosage adjustment required for renal impairment.
No dose adjustment required for renal impairment.
No specific Child-Pugh-based adjustments; use with caution in severe hepatic dysfunction due to potential accumulation.
No dose adjustment required for hepatic impairment.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Approved for acne vulgaris in patients aged 12 years and older: apply 0.1% gel or cream once daily. Safety and efficacy in children under 12 not established.
No specific dose adjustment; use with caution due to age-related comorbidities and potential for increased sensitivity.
No specific dose adjustment; use with caution due to increased risk of skin irritation and dryness in elderly skin.
No FDA boxed warning exists for dehydrated alcohol. However, it should only be administered by physicians experienced in injection techniques for specific indications due to risk of tissue necrosis and nerve damage.
None.
Risk of tissue necrosis and sloughing if extravasation occurs,Neurological injury if injected near nerves (e.g., peripheral nerve damage, paralysis),Hypotension and bradycardia during celiac plexus block,Alcohol intoxication and CNS depression if absorbed systemically,Use with caution in patients with liver disease or diabetes mellitus
Avoid application to cuts, abrasions, eczematous, or sunburned skin.,Avoid excessive exposure to sunlight and UV light; use sunscreen.,Possible local skin reactions: erythema, scaling, dryness, burning, pruritus; dose reduction or interruption may be necessary.,Use caution in patients with eczema.,Not for oral or ophthalmic use.
Hypersensitivity to ethanol or any component of the formulation,Acute infection at the injection site,Uncorrectable coagulation abnormalities,Pregnancy (relative contraindication due to fetal alcohol spectrum disorders)
Hypersensitivity to adapalene or any component of the formulation. Not for use in patients with known sensitivity to retinoids.
No specific food interactions. However, avoid alcohol consumption for 24 hours post-procedure due to risk of additive CNS depression.
No significant food interactions. However, high-fat meals may slightly increase systemic absorption; unlikely to be clinically relevant.
First trimester: Data limited; alcohol is a known teratogen causing fetal alcohol spectrum disorders. Increased risk of congenital anomalies (e.g., heart defects, microcephaly) with high systemic exposure. Second trimester: Continued risk for growth restriction and neurodevelopmental abnormalities. Third trimester: Risk of growth retardation, preterm birth, and neurobehavioral deficits. Avoid systemic use; local injection for nerve block or ablation has minimal systemic absorption but caution advised.
Pregnancy Category C. Animal studies show teratogenicity at high oral doses; topical exposure has minimal systemic absorption. First trimester: risk cannot be ruled out. Second/third trimester: limited data, avoid use. No adequate human studies.
Alcohol is excreted into breast milk; M/P ratio approximately 1.0. Chronic ingestion can impair infant motor development. Dehydrated alcohol for therapeutic injection likely results in negligible systemic levels; however, avoid breastfeeding immediately after procedure. Advise discarding milk for 2-3 hours post-procedure.
Not recommended. Excretion into human milk unknown; low systemic absorption likely but risk to infant cannot be excluded. M/P ratio not established.
No dose adjustment needed for localized injection; pharmacokinetics of ethanol unchanged in pregnancy. Avoid use as systemic agent; use alternative if possible.
Discontinue use. No dosage adjustment studies; topical application is contraindicated regardless of pharmacokinetic changes.
Absolute ethanol (dehydrated alcohol) is used for neurolysis in celiac plexus block for pancreatic cancer pain and for ablation of certain soft tissue lesions. Administer slowly to avoid local toxicity. Inadvertent intravascular injection can cause immediate pain and tissue necrosis. Use ultrasound or CT guidance for accurate placement. Monitor for hypotension, pain, and transient alcohol intoxication. Contraindicated in patients with bleeding disorders or local infection.
Use a pea-sized amount for entire face to avoid irritation. Initiate with lower concentration (0.1% gel) for sensitive skin. Combination with benzoyl peroxide or topical antibiotics may enhance efficacy. Sunscreen is mandatory due to photosensitization. Do not apply to broken, eczematous, or sunburned skin.
You may feel a temporary burning sensation at the injection site.,This medication is used to block pain signals from certain nerves.,Avoid alcohol consumption for 24 hours after the procedure to prevent additive effects.,Report any severe pain, bleeding, or signs of infection to your healthcare provider.,You may experience temporary dizziness or lightheadedness after the injection.
Apply a thin layer once daily at bedtime to clean, dry skin.,Avoid excessive washing or using abrasive cleansers.,Use oil-free, non-comedogenic moisturizers and cosmetics.,Expect initial worsening of acne (retinoid reaction) which resolves in 4-6 weeks.,Sun protection (SPF 30+) and protective clothing are essential daily.,Minimize exposure to extreme wind or cold.,If pregnant, planning pregnancy, or breastfeeding, consult physician before use.,Keep away from eyes, mouth, nasal angles, and mucous membranes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEHYDRATED ALCOHOL vs DIFFERIN, answered by our medical review team.
DEHYDRATED ALCOHOL is a Sclerosing agent that works by Dehydrated alcohol (ethanol) causes tissue necrosis by protein denaturation and cellular dehydration, leading to vascular thrombosis and ischemic infarction. It ablates nerve tissue by extracting lipids and precipitating proteins.. DIFFERIN is a Topical Retinoid that works by Adapalene is a retinoid-like compound that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene expression and normalizing differentiation and proliferation of follicular epithelial cells, reducing comedogenesis and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEHYDRATED ALCOHOL and DIFFERIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEHYDRATED ALCOHOL is: Intravenous administration: 0.1-1 m L of sterile dehydrated alcohol (100% ethanol) injected directly into cystic lesions or tumors under imaging guidance. Maximum volume per injection: 1 m L, repeated up to 3 times per session depending on lesion size.. The standard adult dose of DIFFERIN is: Apply a thin layer of 0.1% gel or cream to affected areas once daily in the evening.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEHYDRATED ALCOHOL and DIFFERIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEHYDRATED ALCOHOL is classified as Category C. First trimester: Data limited; alcohol is a known teratogen causing fetal alcohol spectrum disorders. Increased risk of congenital anomalies (e.g., heart defects, microcephaly) wit. DIFFERIN is classified as Category C. Pregnancy Category C. Animal studies show teratogenicity at high oral doses; topical exposure has minimal systemic absorption. First trimester: risk cannot be ruled out. Second/thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.